Personalised cancer medicine
SE Jackson, JD Chester - International journal of cancer, 2015 - Wiley Online Library
The evolving field of personalised medicine is playing an increasingly important role in
cancer prevention, diagnosis, prognosis and therapeutics. Its importance in clinical …
cancer prevention, diagnosis, prognosis and therapeutics. Its importance in clinical …
Targeted therapies for triple-negative breast cancer: combating a stubborn disease
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
Developing an exclusive sensor based on molecularly imprinted polymer/Multi-walled carbon nanotubes/Fe3O4@ Au nanocomposite for the selective determination …
Determination of pharmaceuticals especially anticancer drugs is one of the important issues
in environmental and medical investigation and creating good information about human …
in environmental and medical investigation and creating good information about human …
Principles of cancer genetics
F Bunz - 2008 - Springer
Mainstream cancer research has long been focused on the biology of the cancer cell. This
approach was logical, as these defective cells harbor the genetic mutations at the root of …
approach was logical, as these defective cells harbor the genetic mutations at the root of …
Predicting and overcoming chemotherapeutic resistance in breast cancer
KH Chun, JH Park, S Fan - Translational Research in Breast Cancer …, 2017 - Springer
Our understanding of breast cancer and its therapeutic approach has improved greatly due
to the advancement of molecular biology in recent years. Clinically, breast cancers are …
to the advancement of molecular biology in recent years. Clinically, breast cancers are …
[HTML][HTML] JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
L Springuel, JC Renauld, L Knoops - haematologica, 2015 - ncbi.nlm.nih.gov
Constitutive JAK-STAT pathway activation occurs in most myeloproliferative neoplasms as
well as in a significant proportion of other hematologic malignancies, and is frequently a …
well as in a significant proportion of other hematologic malignancies, and is frequently a …
Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
With half of the world's population at risk for malaria infection and with drug resistance on the
rise, the search for mutation-resistant therapies has intensified. We report here a therapy for …
rise, the search for mutation-resistant therapies has intensified. We report here a therapy for …
How I treat newly diagnosed chronic myeloid leukemia in 2015
C Gambacorti‐Passerini… - American journal of …, 2015 - Wiley Online Library
The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …
complex process, which includes a prompt and precise diagnosis, the choice among three …
Smooth muscle hyperplasia due to loss of smooth muscle α-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of …
CL Papke, J Cao, CS Kwartler… - Human molecular …, 2013 - academic.oup.com
Mutations in ACTA2, encoding the smooth muscle cell (SMC)-specific isoform of α-actin (α-
SMA), cause thoracic aortic aneurysms and dissections and occlusive vascular diseases …
SMA), cause thoracic aortic aneurysms and dissections and occlusive vascular diseases …
[HTML][HTML] Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment–Implications to its mechanism of action
Imatinib mesylate (IM) is the first developed protein kinase inhibitor and recently it has
topped consumption rates among targeted and total anticancer drugs. Although there are …
topped consumption rates among targeted and total anticancer drugs. Although there are …